Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma

Study Phase: phase 1 and phase 2

Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide

Study design: prospective, multicenter, non-randomized

The REPEAT-study is a prospective, multicenter, non-randomized phase 1 and phase 2 study in which we evaluate the effect of lenalidomide, cyclophosphamide and prednisone (REP-therapy) in patients with relapsed multiple myeloma, previously treated with lenalidomide and refractory to lenalidomide monotherapy.

Inclusion Criteria:

• salmon & Durie stage II/III A or B
• previous lenalidomide refractory disease
• patient commits to pregnancy prevention programme

Exclusion Criteria:

• non-secretory myeloma
• known hypersensitivity to lenalidomide
• inadequate marrow reserve